Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer

Current Opinion in Urology

Volumn 23, Issue 3, 2013, Pages 208-213

  Rove, Kyle O ^a   Crawford, E David ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

androgen deprivation therapy; castrate resistant prostate cancer; metastasis; testosterone

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; DOCETAXEL; DUTASTERIDE; ENZALUTAMIDE; KETOCONAZOLE; PLACEBO; PREDNISONE; TESTOSTERONE;

ADRENAL INSUFFICIENCY; ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; CANCER HORMONE THERAPY; CASTRATION RESISTANT PROSTATE CANCER; DRUG DOSE ESCALATION; EXTERNAL BEAM RADIOTHERAPY; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SEIZURE; TESTOSTERONE BLOOD LEVEL;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84876415432     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32835fa889     Document Type: Review

References (41)

1. Cooperberg M, Broering J, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28:1117- 1123.
2. Lam JS, Leppert JT, Vemulapalli SN, et al. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006; 175:27-34. (Pubitemid 41797079)
3. Sartor AO, Tangen CM, Hussain MHA, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer. J Clin Nurs 2008; 112:2393-2400.
4. Rove KO, Crawford ED. Advanced prostate cancer management. Hosp Phys Urol Board Rev Manual 2012; 15:1-18.
5. Crawford E, EisenbergerMA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321:419-424. (Pubitemid 19211484)
6. Akaza H, Hinotsu S, Usami M, et al. Combined androgen blockade with bicalutamide for advanced prostate cancer. J Clin Nurs 2009; 115:3437- 3445.
7. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995- 2005. A phase 3, randomized controlled trial of abiraterone acetate in the postchemotherapy setting demonstrating an increase in overall survival benefit over placebo. These data resulted in U.S. FDA approval for the drug in this setting.
8. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-1197. A phase 3, randomized controlled trial of enzalutamide in the postchemotherapy setting demonstrating an increase in overall survival benefit over placebo. These data resulted in U.S. FDA approval for the drug in this setting.
9. Roddam AW, Allen NE, Appleby P, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100:157-1157.
10. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 2004; 10:7121-7126. (Pubitemid 39487695)
11. Albisinni S, De Nunzio C, Tubaro A, et al. Greater percentage-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy. Urology 2012; 80:162-168.
12. Schnoeller T, Jentzmik F, Rinnab L, et al. Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer. World J Urol 2012: pp. 1-7.
13. Madan RA, Pal SK, Sartor O, et al. Overcoming chemotherapy resistance in prostate cancer. Clin Cancer Res 2011; 17:3892-3902.
14. Page ST, Lin DW, Mostaghel EA, et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006; 91:3850-3856. (Pubitemid 44536854)
15. Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007; 178:1290-1295. (Pubitemid 47368393)
16. Rove KO, Debruyne FM, Djavan B, et al. Role of testosterone in managing advanced prostate cancer. Urology 2012; 80:754-762. Recent relevant review of literature surrounding evidence for testosterone manipulation and relation to various states of prostate cancer, including development, management and advanced stage disease states.
17. Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-{1-Carboxy-5-[(6-[18F] fluoropyridine- 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res 2011; 17:7645-7653.
18. Ulmert D, Evans MJ, Holland JP, et al. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov 2012; 2:288-290.
19. Ateeq B, Vellaichamy A, Tomlins SA, et al. Role of dutasteride in preclinical ETS fusion-positive prostate cancer models. Prostate 2012; 72:1542-1549.
20. Monk JP, Halabi S, Picus J, et al. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy. Cancer 2011; 118:4139-4147.
21. Clinical Trial NCT00470834: prostate cancer study in men who have failed first-line androgen deprivation therapy. U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT00470834?term=bicalutamidedutasteride& rank=4 [Accessed 28 January 2013].
22. Huggins C, Hodges C. Studies on prostate cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1:293-297.
23. Montgomery R, Mostaghel E, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration- resistant tumor growth. Cancer Res 2008; 68:4447-4454.
24. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69:16-22.
25. Bonkhoff H, Berges R. From pathogenesis to prevention of castration resistant prostate cancer. Prostate 2010; 70:100-112.
26. Mitsiades N, Sung CC, Schultz N, et al. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res 2012; 72:6142-6152.
27. Mohler J, Armstrong A, Mahnson R, et al. NCCN Clinical Practice Guidelines in Oncology: prostate cancer. NCCN.org 2011 pp. 1-59. http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf [Accessed 28 March 2011].
28. Taplin ME, Regan MM, Ko YJ, et al. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15:7099-7105.
29. O'donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17j[alpha]jhydroxylasej[ sol]jC17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004; 90:2317.
30. Ryan C, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castrationresistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28:1481-1488.
31. Attard G, Reid AHM, Yap T, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-4571.
32. Reid AHM, Attard G, Danila D, et al. Significant and Sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28:1489-1495.
33. Danila D, Morris M, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castrationresistant prostate cancer. J Clin Oncol 2010; 28:1496-1501.
34. Pazdur R. FDA approval for abiraterone acetate. National Cancer Institute 2012. http://www.cancer.gov/cancertopics/druginfo/fda-abirateroneacetate [Accessed 16 December 2012].
35. Tran C, Ouk S, Clegg N, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324:787.
36. Kelly WK, Slovin S, Scher HI. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol Clin N Am 1997; 24:421-431. (Pubitemid 27169267)
37. Taplin M-E, Montgomery RB, Logothetis CJ, et al. Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): results of a randomized phase II study. ASCO Meeting Abstracts 2012; 30:4521.
38. Saylor PJ, Kaufman DS, Michaelson MD, et al. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol 2010; 183:2200-2205.
39. Corona G, Gacci M, Baldi E, et al. Androgen deprivation therapy in prostate cancer: focusing on sexual side effects. J Sex Med 2012; 9:887-902.
40. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009; 15:4792-4798.
41. Kamiya N, Suzuki H, Endo T, et al. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade. Int J Urol 2011; 19:169-173.